Applied DNA Sciences Inc. Releases 2025 Annual Report: Strategic Restructuring and Financial Performance Highlighted
Applied DNA Sciences Inc. (NASDAQ: APDN), a biotechnology company specializing in DNA and RNA production and detection technologies, has released its annual report for the fiscal year ending September 30, 2025. The report outlines significant restructuring efforts, a strategic shift toward digital asset management, and a mixed financial performance.
1. Company Overview
Applied DNA Sciences operates primarily through its subsidiary, LineaRx, which focuses on commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company aims to leverage proceeds from operational cash flow to strategically accumulate BNB, the native cryptocurrency of the Binance blockchain ecosystem, as part of its transition towards managing digital assets.
2. Strategic Restructuring
In a decisive move to streamline operations, Applied DNA Sciences announced on February 13, 2025, its exit from the DNA Tagging and Security Products and Services segment. This restructuring included a workforce reduction of approximately 20%. Following this, on June 27, 2025, an additional workforce reduction of 27% was implemented, ceasing operations at Applied DNA Clinical Labs (ADCL).
In October 2025, the Board authorized another restructuring plan, aiming for a further 60% workforce reduction. These actions are expected to yield annualized cost savings of approximately $2.8 million, although pre-tax charges of about $1.4 million related to severance and employee benefits will be incurred.
3. Launch of BNB Strategy
The company's new focus on digital asset management culminated in the launch of its BNB strategy in October 2025. This initiative closed a private placement that generated $26.8 million in cash and crypto assets, with potential additional gross proceeds of up to $30.8 million from future warrant exercises. The strategy aims to manage digital assets, primarily BNB, through staking and participation in Binance ecosystem opportunities.
4. Financial Performance Overview
For the fiscal year 2025, Applied DNA Sciences reported total product revenues of $1,424,147, reflecting a 33% increase compared to the previous year. This growth was primarily fueled by increased shipments in the Therapeutic DNA Production Services segment. However, service revenues saw a decline of 31%, totaling $712,788, largely due to reduced activity in the DNA Tagging and Security Products segment.
Key Financial Metrics
- Gross Profit: Decreased by 14% to $838,907, reflecting a change in product mix and a significant drop in service revenue.
- Research and Development Expenses: Increased by 67% to $6,016,912, predominantly due to a $2.7 million impairment charge related to in-process research and development.
- Loss from Operations: Increased to $16,046,595, a 17% rise from the prior year.
Income Statement Highlights
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $2.13M | $3.43M |
| Operating Income | $(16.04M) | $(14.02M) |
| Net Income to Common | $(69.48M) | $(7.22M) |
| Dec 2024 | Dec 2025 | |
|---|---|---|
Net Income | -6.99M | -15.16M |
Net Income to Non-controlling Interest | -95.78K | -188.5K |
Profit | -7.08M | -15.34M |
Net Income Discontinued | 0 | -392.7K |
Net Income Continuing | -7.08M | -14.95M |
Income Tax Expense | 0 | -684.1K |
Pretax Income | -7.08M | -15.64M |
Non-operating Income | 6.93M | 405.9K |
Operating Income | -14.02M | -16.04M |
Revenue | 3.43M | 2.13M |
Costs and Expenses | 17.45M | 18.18M |
Cost of Revenue | 2.41M | 1.29M |
Operating Expenses | 15.04M | 16.88M |
Research & Development | 3.59M | 6.01M |
Selling, General & Administrative | 11.44M | 10.86M |
Geographic and Segment Revenue Breakdown
The company's revenue by geography in 2025 shows a concentrated focus on the Americas and Asia, with a significant decline in European revenue:
- Americas: $1.01M
- Asia and Other: $1.02M
- Europe: $105.5K
In terms of segments, the Therapeutic DNA Production segment outperformed the DNA Tagging and Security Products segment:
- Therapeutic DNA Production: $988.1K
- DNA Tagging and Security Products: $1.14M
Revenue by Products and Services
Revenue generated from products and services reflected varied performance:
- Large Scale DNA Production: $612.3K
- Research and Development Services: $375.7K
- Supply Chain: $1.14M
5. Balance Sheet Snapshot
As of September 30, 2025, Applied DNA Sciences reported total assets of $4.43 million, down from $12.78 million in 2024. Liabilities stood at $2.49 million, with total equity decreasing to $1.94 million.
| Metric | 2025 | 2024 |
|---|---|---|
| Total Assets | $4.43M | $12.78M |
| Total Liabilities | $2.49M | $3.82M |
| Total Equity | $1.94M | $8.96M |
| Dec 2024 | Dec 2025 | |
|---|---|---|
Total Assets | 12.78M | 4.43M |
Total Current Assets | 8.04M | 2.23M |
Cash and Equivalents | 6.43M | 1.66M |
Net Inventories | 438.5K | 84.10K |
Accounts Receivable | 362.0K | 237.4K |
Prepaid Expenses | 815.9K | 242.1K |
Other Current Assets | 0 | 6.97K |
Total Non-current Assets | 4.74M | 2.19M |
Intangible Assets | 2.69M | 0 |
Net PP&E | 553.2K | 242.7K |
Lease Assets | 739.1K | 193.2K |
Other Non-current Assets | 750K | 1.76M |
Total Liabilities and Equity | 12.78M | 4.43M |
Total Liabilities | 3.82M | 2.49M |
Total Current Liabilities | 2.39M | 2.46M |
Accounts Payable and Accrued Liabilities | 1.79M | 2.25M |
Current Debt | 545.9K | 193.2K |
Current Deferred Revenue | 58.78K | 12.28K |
Total Non-current Liabilities | 1.42M | 31.83K |
Non-current Accounts Payable and Accrued Liabilities | 31.46K | 31.46K |
Non-current Deferred Revenue | 194K | 0 |
Non-current Deferred Tax Liabilities | 684.1K | 0 |
Other Non-current Liabilities | 513.2K | 370 |
Total Equity and Non-controlling Interests | 8.96M | 1.94M |
Total Equity | 9.14M | 2.30M |
Non-controlling Interests | -174.5K | -363.0K |
6. Cash Flow Analysis
The cash flow statement reflects a net change in cash of -$4.75 million for 2025, primarily due to negative cash from operating activities:
| Metric | 2025 | 2024 |
|---|---|---|
| Net Change in Cash | $(4.75M) | $(720.7K) |
| Net Cash from Operating Activities | $(12.24M) | $(13.71M) |
| Dec 2024 | Dec 2025 | |
|---|---|---|
Net Change in Cash | -720.7K | -4.75M |
Net Cash from Operating Activities | -13.71M | -12.24M |
Operating Profit | -7.08M | -15.34M |
Adjustment to Operating Profit | -6.62M | 3.10M |
Net Cash from Investing Activities | -407.9K | -313.1K |
Productive Assets | 407.9K | 313.1K |
Net Cash from Financing Activities | 13.39M | 8.05M |
Equity Issuance/Repurchase | 15.03M | 2.50M |
Other Financing Activities | -1.63M | 5.54M |
7. Challenges and Future Outlook
Despite a notable increase in product revenues, Applied DNA Sciences faces significant challenges, including recurring net losses leading to an accumulated deficit of $379.16 million as of September 30, 2025. The company’s future strategy will emphasize its BNB strategy and the commercialization of its Therapeutic DNA Production Services, with anticipated investments in research and development activities.
As it navigates these challenges, the emphasis on strategic partnerships and enhanced capabilities at LineaRx may position Applied DNA Sciences for a more robust recovery in upcoming years.
